Sp1048
AGA GUIDELINE: INTESTINAL MICROBIOTA TRANSPLANTATION (IMT)
Date
May 9, 2023
Explore related products in the following collection:
Society: AGA
AGA guidelines are among the most rigorously evidence-based and trusted guidelines in the field of GI and hepatology. This session will give DDW attendees the rare opportunity to hear about newly published and upcoming AGA guidelines from the authors of the guideline themselves, including a Question and Answer portion. It also provides an additional public forum to have the guidelines heard and discussed, in addition to our 30-day public comment period, contributing to an open and transparent process of guideline development.
AGA guidelines are among the most rigorously evidence-based and trusted guidelines in the field of GI and hepatology. This session will give DDW attendees the rare opportunity to hear about newly published and upcoming AGA guidelines from the authors of the guideline themselves, including a Question and Answer portion. It also provides an additional public forum to have the guidelines heard and discussed, in addition to our 30-day public comment period, contributing to an open and transparent process of guideline development.
Presenters
Washington University in St Louis
University of North Carolina
Tracks
Related Products
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
